Neue Influenza A/H1N1: alles unter Kontrolle?

H1N1 - Impfung - Pandemie

H1N1 - immunization - pandemia

Literatur

• 1 Leroux-Roels I, Borkowski A. et al . Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine.  Lancet. 2007;  370 580-589
• 2 Fazekas G, Martosne-Mendi R, Jankovics I. et al . Cross-reactive immunity to clade 2 strains of influenza virus A subtype H5N1 induced in adults and elderly patients by Fluval, a prototype pandemic influenza virus vaccine derived by reverse genetics, formulated with a phosphate adjuvant, and directed to clade 1 strains.  Clin Vaccine Immunol. 2009;  16 437-443
• 3 Jain S, Kamimoto L, Bramley A M. et al . Hospitalized Patients with 2009 H1N1 Influenza in the United States, April-June 2009.  N Engl J Med. 2009 Oct 8. [Epub ahead of print]; 
• 4 Birnkrant D, Cox E. The Emergency Use Authorization of Peramivir for Treatment of 2009 H1N1 Influenza.  N Engl J Med. 2009 Nov 3. [Epub ahead of print]; 
• 5 The Australia and New Zealand Extracorporeal Membrane Oxygenation (ANZ ECMO) Influenza Investigators . Extracorporeal Membrane Oxygenation for 2009 Influenza A (H1N1) Acute Respiratory Distress Syndrome.  JAMA. 2009;  302 1888-1895
• 6 Vaillant L. et al . Epidemiology of fatal cases associated with pandemic H1N1 influenza 2009.  Euro Surveill. 2009;  14 pii 19309
• 7 The ANZIC Influenza Investigators . Critical Care Services and 2009 H1N1 Influenza in Australia and New Zealand.  N Engl J Med. 2009 Oct 8. [Epub ahead of print];